Andréas Mackensen

Friedrich-Alexander-Universität Erlangen-Nürnberg

Also affiliated with Universitätsklinikum Erlangen

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors”.

611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed/refractory CLDN6+ solid tumors

Annals of Oncology(2024)10.1016/j.annonc.2024.08.678

N/A

0DataRank · unranked

13 citations

Andréas Mackensen, C. Schultze-Florey, Winfried Alsdorf, E. Wagner-Drouet, Daniel Heudobler +15 more